| Seizures, Focal
Aptiom vs Vimpat
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Aptiom vs Vimpat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimpat has a higher rate of injection site reactions vs Aptiom based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimpat but not Aptiom, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aptiom
Vimpat
At A Glance
Oral
Once daily
Sodium channel inhibitor
Oral; IV infusion
Twice daily
Sodium channel modulator
Indications
- Seizures, Focal
- Seizures, Focal
- Idiopathic generalized epilepsy
Dosing
Seizures, Focal (Adults) Initial 400 mg orally once daily; may initiate at 800 mg once daily if need for seizure reduction outweighs increased adverse reaction risk; increase weekly by 400-600 mg to recommended maintenance of 800-1600 mg once daily.
Seizures, Focal (Pediatric, 4-17 years) Weight-based once daily oral dosing; initial dose and titration increments per weight table; maintenance 400-1200 mg/day depending on body weight range (11-21 kg: 400-600 mg; 22-31 kg: 500-800 mg; 32-38 kg: 600-900 mg; >38 kg: 800-1200 mg).
Renal Impairment (Moderate or Severe) Reduce dosage by 50% in patients with creatinine clearance below 50 mL/min.
Seizures, Focal Monotherapy (adults >=17 years): initiate 100 mg twice daily, maintenance 150-200 mg twice daily (300-400 mg/day); adjunctive therapy (adults): initiate 50 mg twice daily, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients 1 month to <17 years: weight-based dosing twice daily; max 200 mg twice daily; IV infusion available at same dose when oral temporarily not feasible.
Idiopathic generalized epilepsy Adjunctive therapy only for patients 4 years of age and older; adults: initiate 50 mg twice daily, titrate by 50 mg twice daily weekly, maintenance 100-200 mg twice daily (200-400 mg/day); pediatric patients: weight-based dosing twice daily.
Contraindications
- Hypersensitivity to eslicarbazepine acetate or oxcarbazepine
—
Adverse Reactions
Most common (>=4%) dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, tremor
Serious suicidal behavior and ideation, serious dermatologic reactions, DRESS/multiorgan hypersensitivity, anaphylactic reactions and angioedema, hyponatremia, drug-induced liver injury, abnormal thyroid function, pancytopenia, agranulocytosis, leukopenia
Postmarketing leukopenia, agranulocytosis, thrombocytopenia, megaloblastic anemia, pancytopenia, syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Most common (>=2%) dizziness, headache, nausea, diplopia, ataxia, somnolence, vomiting, fatigue, blurred vision, vertigo, tremor, nystagmus, balance disorder
Serious suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, DRESS/multiorgan hypersensitivity reactions
Postmarketing agranulocytosis, aggression, agitation, hallucination, insomnia, psychotic disorder, angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis, dyskinesia, new or worsening seizures
Pharmacology
APTIOM is extensively converted to its active metabolite eslicarbazepine after oral administration; eslicarbazepine exerts anticonvulsant activity thought to involve inhibition of voltage-gated sodium channels.
Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing; it is a functionalized amino acid antiepileptic agent.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aptiom
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Vimpat
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Aptiom
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Vimpat
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Aptiom
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vimpat
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$35/fillfill
Aptiom High-Deductible Discount CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Vimpat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AptiomView full Aptiom profile
VimpatView full Vimpat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.